



Docket No. 239620US0/hc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Shigehiko IMAGAWA, et al.

SERIAL NO: 10/607,996

GAU: 1614

FILED: June 30, 2003

EXAMINER:

FOR: ERYTHROPOIETIN PRODUCTION POTENTIATOR

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Rohitha Jayasuriya
Registration No. 50,385



DOCKET NO.: 239620US0/hd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Shigehiko IMAGAWA, et al.

SERIAL NO: 10/607,996

GROUP: 1614


FILED: June 30, 2003

EXAMINER:

FOR: ERYTHROPOIETIN PRODUCTION POTENTIATOR

STATEMENT OF RELEVANCY

All references on Form 1449 are discussed in the specification.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

239620US0

SERIAL NO.

10/607,996

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Shigehiko IMAGAWA, et al.

FILING DATE

June 30, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AJ					
	AK					
	AL					
	AM					
	AN					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AO	F-K. LIN, et al., Proc. Natl. Acad. Sci., vol. 82, pages 7580-7584, "CLONING AND EXPRESSION OF THE HUMAN ERYTHROPOIETIN GENE", November 1985
AP	J. W. ESCHBACH, et al., The New England Journal of Medicine, vol. 316, no. 2, pages 73-78, "CORRECTION OF THE ANEMIA OF END-STAGE RENAL DISEASE WITH RECOMBINANT HUMAN ERYTHROPOIETIN", January 8, 1987
AQ	J. W. ESCHBACH, et al., Annals of Internal Medicine, vol. 11, no. 12, pages 992-1000, "RECOMBINANT HUMAN ERYTHROPOIETIN IN ANEMIC PATIENTS WITH END-STAGE RENAL DISEASE", December 15, 1989
AR	V. S. LIM, et al., Annals of Internal Medicine, vol. 110, no. 2, pages 108-114, "RECOMBINANT HUMAN ERYTHROPOIETIN TREATMENT IN PRE-DIALYSIS PATIENTS", January 15, 1989
AS	R. P. DANNA, et al., Erythropoietin in Clinical Applications, An International Perspective, pages 301-324, "ERYTHROPOIETIN THERAPY FOR THE ANEMIA ASSOCIATED WITH AIDS AND AIDS THERAPY AND CANCER", 1990
AT	J. L. SPIVAK, et al., Blood, vol. 73, no. 1, pages 90-99, "THE IN VIVO METABOLISM OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE RAT", January 1989
AU	F. G. McMAHON, et al, Blood, vol. 76, no. 9, pages 1718-1722, "PHARMACOKINETICS AND EFFECTS OF RECOMBINANT HUMAN ERYTHROPOIETIN AFTER INTRAVENOUS AND SUBCUTANEOUS INJECTIONS IN HEALTHY VOLUNTEERS", November 1, 1990

☐ Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.